Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP004
- Development stage
- Preclinical
- Lead developer
- Endpoint Health
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EP004 is a first-in-class monoclonal antibody that selectively inhibits tissue factor (TF)-dependent intracellular signaling. It is designed to reduce inflammation by targeting tissue factor, a key mediator of innate immune activity and coagulation involved in inflammation, chemotaxis, and hemostasis across multiple immune-mediated inflammatory diseases (IMIDs) such as ulcerative colitis, Crohn’s disease, lupus, and certain vasculitides. EP004 aims to decrease pro-inflammatory cytokines and chemokines without interfering with the hemostasis-related functions of the TF pathway. The drug was initially developed by Iconic Therapeutics and is now under development by Endpoint Health using a precision AI platform to identify responders across autoimmune indications. It is currently completing IND-enabling studies with an expected IND submission in 2023[2][3].
- Other names
- ICON-4ICON4ICON 4
02
Targets
F3 (Tissue factor)
Beyond the preview
Go deeper on EP004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP004.